A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744

Alzheimer’s disease

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134

Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census

Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168

Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease

Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207

Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., Andrieu, P. D. S. I., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E. G., Holsztynska, E. J., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00012.x · Cited by 870

The discovery and development of HMG-CoA reductase inhibitors.

Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847

Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation

Wong, G. T., Manfra, D. J., Poulet, F. M., Zhang, Q., Josien, H. B., Bara, T. A., Engstrom, L., Pinzon-Ortiz, M. C., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 723

Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599

NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications

Skovronsky, D., Lee, V. M. ‐., & Trojanowski, J. Q. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 433

Alzheimer Disease

Savonenko, A. V., Melnikova, T., Li, T., Price, D. L., & Wong, P. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00021-5 · Cited by 20

Amyloid beta peptide-degrading microbial enzymes and its implication in drug design

Dhanavade, M. J., & Sonawane, K. D. (2020) · 3 Biotech · doi:10.1007/s13205-020-02240-2 · Cited by 16

Therapeutic potential of enzymes, neurosteroids, and synthetic steroids in neurodegenerative disorders: A critical review

Servi, R., Akkoç, R. F., Aksu, F., & Servi, S. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106766 · Cited by 16

A new methodology for simultaneous quantification of total-Aβ, Aβx-38, Aβx-40, and Aβx-42 by column-switching LC/MS/MS

Watanabe, K., Ishikawa, C., Kuwahara, H., Sato, K., Komuro, S., Nakagawa, T., Nomura, N., Watanabe, S., & Yabuki, M. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5648-1 · Cited by 15

Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators (Part 2)

Takai, T., Koike, T., Nakamura, M., Kajita, Y., Yamashita, T., Taya, N., Tsukamoto, T., Watanabe, T., Murakami, K., Igari, T., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.040 · Cited by 14

An internal docking site stabilizes substrate binding to γ-secretase: Analysis by molecular dynamics simulations

Chen, S., & Zacharias, M. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.05.023 · Cited by 14

Biomarkers of the Dementia

Shoji, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/564321 · Cited by 15

Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice

Huang, M., Tallon, C., Zhu, X., Huizar, K. D. J., Picciolini, S., Thomas, A. G., Tenora, L., Liyanage, W., Rodà, F., Gualerzi, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092364 · Cited by 11

A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human

Karelina, T., Demin, O. O., Nicholas, T., Lu, Y., Duvvuri, S., & Barton, H. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12211 · Cited by 13

Clinical trials in Alzheimer's disease

Delrieu, J., & Vellas, B. J. (2015) · Wiley eBooks · doi:10.1002/9781118323434.ch9 · Cited by 13

Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation

Hajós, M., Morozova, E., Siok, C. J., Atchison, K. P., Nolan, C. E., Riddell, D. R., Kiss, T., & Hajós‐Korcsok, É. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00072 · Cited by 12

Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications

Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990141 · Cited by 12

CD51 Intracellular Domain Promotes Cancer Cell Neurotropism through Interacting with Transcription Factor NR4A3 in Colorectal Cancer

Huang, T., Lin, Y., Chen, J., Hu, J., Chen, H., Zhang, Y., Zhang, B., & He, X. (2023) · Cancers · doi:10.3390/cancers15092623 · Cited by 12

Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.

Fan, L., & Chiu, M. (2010) · PubMed · Cited by 11

Camptothecin and its Analogs Reduce Amyloid-β Production and Amyloid-β42-Induced IL-1β Production

Wang, J., Shi, Z., Zhang, M., Xin, G.-Z., Pang, T., Zhou, P. H., Chen, J., Qi, L., Yang, H. Q., Xu, X., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140078 · Cited by 13

Multiplexing and multivariate analysis in neurodegeneration

Andréasson, U., Portelius, E., Pannee, J., Zetterberg, H., & Blennow, K. (2012) · Methods · doi:10.1016/j.ymeth.2012.02.004 · Cited by 12

Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease

Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14

In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid

Lehmann, S., Hirtz, C., Vialaret, J., Ory, M., Gras-Combe, G., Corre, M. L., Badiou, S., Cristol, J., Hanon, O., Cornillot, E., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03328 · Cited by 11

Drug Treatments in Development for Alzheimer's Disease

Woodward, M. C. (2012) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2012.tb00133.x · Cited by 12

Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators

Rynearson, K. D., Buckle, R. N., Herr, R. J., Mayhew, N. J., Chen, X., Paquette, W. D., Sakwa, S. A., Yang, J., Barnes, K. D., Nguyen, P. A. H., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115734 · Cited by 11

Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease

Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11

Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective

Hampel, H. J., & Prvulovic, D. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0021-4 · Cited by 11

Semagacestat Pharmacokinetics Are Not Significantly Affected by Formulation, Food, or Time of Dosing in Healthy Participants

Willis, B. A., Zhang, W., Ayan‐Oshodi, M., Lowe, S. L., Annes, W. F., Sirois, P. J., Friedrich, S. W., & de la Peña, A. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011407195 · Cited by 11

The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board

Schmidt, M. E., Siemers, E., Snyder, P. J., Potter, W. Z., Cole, P. E., & Soares, H. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.010 · Cited by 11

Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

Broeck, B. V., Timmers, M., Ramael, S., Bogert, J., Shaw, L. M. J., Mercken, M. H., Slemmon, J., Nueten, L. V., Engelborghs, S., & Streffer, J. R. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0184-z · Cited by 11

Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer’s Disease: Clinical Molecular and Genetic Studies on Alzheimer’s Disease

Shoji, M. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r13fm · Cited by 10

The amyloid-β peptide: Guilty as charged?

Murphy, M. P., Buzinova, V. A., & Johnson, C. E. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166945 · Cited by 12

Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease

Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10

Pathology Associated with AAV Mediated Expression of Beta Amyloid or C100 in Adult Mouse Hippocampus and Cerebellum

Drummond, E., Muhling, J., Martins, R. N., Wijaya, L. K., Ehlert, E., & Harvey, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059166 · Cited by 11

Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo

Huang, Y., Li, T., Eatherton, A. J., Mitchell, W. L., Rong, N., Ye, L., Yang, X., Jin, S., Ding, Y., Zhang, J., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.003 · Cited by 10

Protein production is an early biomarker for RNA ‐targeted therapies

Self, W. K., Schoch, K. M., Alex, J., Barthélemy, N. R., Bollinger, J. G., Sato, C., Cole, T. A., Kordasiewicz, H. B., Swayze, E. E., Bateman, R. J., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.657 · Cited by 9

The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat

Tai, L. M., Jacobsen, H., Ozmen, L., Flohr, A., Jakob‐Roetne, R., Caruso, A., & Grimm, H. P. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9246-4 · Cited by 9

21st Century Cures Act and similar policy efforts: at what cost?:

Zuckerman, D. M., Jury, N. J., & Silcox, C. (2015) · BMJ · doi:10.1136/bmj.h6122 · Cited by 9

Alzheimer diseases

Savonenko, A. V., Wong, P. C., & Li, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00022-8 · Cited by 8

Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach

Cummings, J. L. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000507569 · Cited by 9

Current Paradigms to Explore the Gut Microbiota Linkage to Neurological Disorders

Sharma, V., Sankhyan, A., Varshney, A., Choudhary, R., & Sharma, A. K. (2020) · EMJ Neurology · doi:10.33590/emjneurol/20-00068 · Cited by 9

Neurobiology of Alzheimer’s Disease

Wong, P. C., Savonenko, A. V., Li, T., & Price, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00046-8 · Cited by 9

Interactions between daily sleep-wake rhythms, γ-secretase, and amyloid-β peptide pathology point to complex underlying relationships

Turton, S. M., Padgett, S., Jessup, M. T., Johnson, C. E., Buzinova, V. A., Barth, S. E., Köhler, K., Spearman, H. M., Macheda, T., Manauis, E. C., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167840 · Cited by 7

Neuroproteomic tools for battling Alzheimer's disease

Veenstra, T. D. (2016) · PROTEOMICS · doi:10.1002/pmic.201600211 · Cited by 8

Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer’s Disease, Using the Physiologically Based LeiCNS-PK3.0 Model

Saleh, M. A. A., Bloemberg, J. S., Elassaiss‐Schaap, J., & de Lange, E. C. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03281-3 · Cited by 8

Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?

Ross, J., & Imbimbo, B. P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101548 · Cited by 8

Design and synthesis of piperazine derivatives as a novel class of γ-secretase modulators that selectively lower Aβ42 production

Takai, T., Koike, T., Honda, E., Kajita, Y., Nakamura, M., Morimoto, S., Hoashi, Y., Kamata, M., Watanabe, T., Igari, T., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.055 · Cited by 8

Enzyme Inhibitors Involved in the Treatment of Alzheimer’s Disease

Revadigar, V., Ghalib, R. M., Murugaiyah, V., Embaby, M. A., Jawad, A. H., Mehdi, S. H., Hashim, R., & Sulaiman, O. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50003-9 · Cited by 9

Using stable isotope labeling to advance our understanding of Alzheimer’s disease etiology and pathology

Hark, T. J., & Savas, J. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15298 · Cited by 7

Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease

Adeniji, A. O., Adams, P. W., & Mody, V. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00007-6 · Cited by 7

Fractional synthesis and clearance rates for amyloid β

Edland, S. D., & Galasko, D. R. (2011) · Nature Medicine · doi:10.1038/nm.2495 · Cited by 7

Clinical Trials and Drug Development

Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100301 · Cited by 8

Neuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRIPreprint

McKay, N. S., Gordon, B. A., Hornbeck, R. C., Jack, C. R., Koeppe, R. A., Flores, S. E., Keefe, S., Hobbs, D. A., Joseph‐Mathurin, N., Wang, Q., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.25.485799 · Cited by 9

Alzheimer’s Disease and Animal Models in Retrospect

Fajemiroye, J. O. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000215 · Cited by 6

In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

Hyde, L. A., Zhang, Q., Vecchio, R. A. D., Leach, P. T., Cohen-Williams, M. E., Chen, L., Wong, G. T., McHugh, N. A., Chen, J., Higgins, G. A., et al. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/823528 · Cited by 6

Dose ranging for trials through biomarkers of drug effects

Potter, W. Z. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0070-5 · Cited by 6

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer’s disease clinical trials

Olsson, B., Schott, J. M., Blennow, K., & Zetterberg, H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341311 · Cited by 7

Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date

Boersema, P. J., Melnik, A., Hazenberg, B. P. C., Rezeli, M., Marko‐Varga, G., Kamiie, J., Portelius, E., Blennow, K., Zubarev, R. A., Polymenidou, M., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00401 · Cited by 6

Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein

Xie, Y., Wang, Y., Jiang, S., Xiang, X., Wang, J., & Ning, L. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1973482 · Cited by 6

Pharmacological treatment for Alzheimer’s disease

Kulkantrakorn, K. (2014) · Asian Medical Journal and Alternative Medicine · doi:10.70933/2773-9465.1545 · Cited by 6

Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States

Aso, E., & Ferrer, I. (2013) · InTech eBooks · doi:10.5772/54783 · Cited by 5

The Ups and Downs of Amyloid in Alzheimer's

Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5

Comparative functional genomic analysis of Alzheimer’s affected and naturally aging brains

Peng, Y.-S., Tang, C.-W., Peng, Y.-Y., Chang, H., Chen, C., Guo, S., Wu, L.-C., Huang, M.-C., & Lee, H.-C. (2020) · PeerJ · doi:10.7717/peerj.8682 · Cited by 5

The roles of biomarkers in Alzheimer's disease clinical trials

Cummings, J. L., Sharma, S., DeAndrea, G., Osse, A. M. L., & Ortiz, A. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00811 · Cited by 4

The manipulator behind “Scissors”: γ -secretase and its modulators in Alzheimer’s disease

Ning, G., Fan, X., Du, J., wenxue, Z., Sijia, W., Meinei, C., Xiaolong, D., & Yiming, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637671 · Cited by 5

Peering inside Alzheimer's brains

Sinha, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.1863 · Cited by 4

Mining the secrets of the CSF: developing biomarkers of neurodegeneration

Potter, W. Z. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65309 · Cited by 4

Curcumin Offers Potential Efficacy for Treating Alzheimer’s Disease

Potter, P. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815461-8.00010-4 · Cited by 4

Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development

Liao, F., & Holtzman, D. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2802 · Cited by 4

Proposed Therapeutic Strategy to Combat Alzheimer’s Disease by Targeting Beta and Gamma Secretases

Kumar, D., Anand, P., & Singh, S. K. (2025) · Current Alzheimer Research · doi:10.2174/0115672050380899250602042028 · Cited by 3

A Semi‐Physiological Model of Amyloid‐β Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development

Haug, K. G., Staab, A., Dansirikul, C., & Lehr, T. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.91 · Cited by 3

Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment

Lewczuk, P. (2014) · Advances in Geriatrics · doi:10.1155/2014/891780 · Cited by 3

Progress in the development of anti-amyloid drugs for treatment of Alzheimer’s disease

Shitaka, Y., Mitani, Y., Nagakura, A., Miyake, A., & Matsuoka, N. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.15 · Cited by 3

Computational Modeling of Gamma-Secretase Inhibitors as Anti-Alzheimer Agents

Manoharan, P., & Ghoshal, N. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_12 · Cited by 3

Alzheimer’s Disease: Causes, Mechanisms, and Steps Toward Prevention

Choi, S. H., & Tanzi, R. E. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190069162.013.18 · Cited by 3

Omega 3 PUFA

Chaudhary, V., Nigam, A. K., Paliwal, A., Singh, M. K., Gour, J. K., & Sinha, V. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819212-2.00005-0 · Cited by 4

Reply to: Fractional synthesis and clearance rates for amyloid β

Elbert, D. L., Patterson, B. W., Ercole, L., Ovod, V., Kasten, T., Mawuenyega, K., Yarasheski, K., Morris, J. C., Benzinger, T., Holtzman, D. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2496 · Cited by 3

Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology

Bateman, R. J., West, T., Yarasheski, K. E., Patterson, B. W., Lucey, B. P., Cirrito, J. R., Lehmann, S., Hirtz, C., Gabelle, A., Miller, T. M., et al. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00011-4 · Cited by 3

Biomarkers in Alzheimer’s Disease—Perspectives for the Future

Cummings, J. L. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.23 · Cited by 2

Biomarker utility in Alzheimer's disease clinical trials

Soares, H. D., & Lovestone, S. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.09.002 · Cited by 2

γ-secretase inhibitors for treating Alzheimer’s disease: rationale and clinical data

Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Clinical Investigation · doi:10.4155/cli.11.86 · Cited by 2

Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 2

In response to “a gamma‐secretase inhibitor decreases amyloid‐beta production in the central nervous system”

Raybon, J. J., & Albright, C. F. (2010) · Annals of Neurology · doi:10.1002/ana.21929 · Cited by 2

The Innate Immune Protein IFITM3 as a γ-Secretase Modulatory Protein: From Inflammation to Alzheimer’s Disease

Choi, J.-S., & Hur, J. (2026) · DNA and Cell Biology · doi:10.1177/10445498261456523 · Cited by 1

Amyloid-Related Imaging Abnormalities Associated With Immunotherapy In Alzheimer‘s Disease Patients

Panza, F., Frisardi, V., Imbimbo, B. P., Logroscino, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2012) · Future Neurology · doi:10.2217/fnl.12.42 · Cited by 1

Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics

Yuen, E., Liu, E., & Kinney, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_14 · Cited by 1

Strategies for Inhibiting Protein Aggregation: Therapeutic Approaches to Protein-Aggregation Diseases

Lanning, J. D., & Meredith, S. C. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_14 · Cited by 1

Rule-based modelling and simulation of drug-administration policies

Bortolussi, L., Krüger, T. B., Lehr, T., & Wolf, V. (2015) · ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) · doi:10.5555/2873003.2873012 · Cited by 1

Small molecule NPT-440-1 inhibits ionic flux through Aβ 1-42 pores: Implications for Alzheimer's disease therapeutics

Gillman, A. L., Lee, J., Ramachandran, S., Capone, R. F., Gonzalez, T., Wrasidlo, W., Masliah, E., & Lal, R. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.06.001 · Cited by 1

Design, Synthesis and Biological Evaluation of Nobiletin Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Zhou, L., Shi, X., Yin, H., Huang, Y., Wang, R., & Ma, L. (2021) · ChemistrySelect · doi:10.1002/slct.202004239 · Cited by 1

Frontiers in Clinical Drug Research - Alzheimer Disorders

Atta-ur-rahman, Mavoungou, C., Zimmerman, K. S., Wright, J., Harding, J., Cavallaro, R., Fuso, A., Yoshiyama, Y., Asija, Z., Clifford, A., et al. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816810806801150301 · Cited by 1

A Change of Mind: Targeting Amyloid-β with Better Safety Profile

Krick, K. E., & Wilcock, D. M. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-113434 · Cited by 1

The future of dementia prevention and treatment strategies

直行, 里. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.374 · Cited by 1

Blood-Brain Barrier Permeability and Inflammation in Cerebral Small Vessel Disease

Walsh, J. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.50869 · Cited by 2

Mass Spectrometry-Based Quantification of Orexin Species in Human Cerebrospinal Fluid Reveals Differential Dynamics Associated with SleepPreprint

Horie, K., Koppisetti, R. K., Steger, C. J., Plazzi, G., & Lucey, B. P. (2025) · medRxiv · doi:10.64898/2025.12.06.25341754 · Cited by 1

Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints

da Silva, D. L. G. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)

Failure of Biomarkers in Clinical Trials of Alzheimer's Disease: Blaming the Messenger?

Quinn, J. F., & Clark, C. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1128

Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease

Robichaud, A. J., Kim, J., & Jacobsen, J. S. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc249

Identification of Novel Fluid Biomarkers for Alzheimer's Disease

Craig‐Schapiro, R. (2012) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7pr7t12

Characterising transgenic APP mutation mouse models of amyloid pathology for use in preclinical immunotherapy

Hvoslef‐Eide, M. (2012) · ORCA Online Research @Cardiff (Cardiff University)

Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism

Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk

Cerebrospinal Fluid Biomarkers to Monitor Treatment Effects in Alzheimer’s Disease and Related Conditions

Mattsson, N., Portelius, E., Blennow, K., & Zetterberg, H. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.75

The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration

Martone, R. L., Snyder, R. H., Xu, A. S. L., & Reams, R. Y. (2012) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-012-0015-4

TREATMENTS FOR ALZHEIMER’S DISEASE: AN OVERVIEW

Nandagopan, G. L., kishore, A., Manavalan, M., & Najeeb, M. A. (2013) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.04504

Commentary on “Biomarkers in Alzheimer's disease drug development.” Can't live without 'em

Aisen, P. S. S. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.006

Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

Siemers, E., Quinn, J. F., Kaye, J. A., Farlow, M. R., Porsteinsson, A. P., Tariot, P. N., Zoulnouni, P., Galvin, J. E., Holtzman, D. M., Knopman, D. S., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000198762.41312.e1 · Cited by 291

In response to “a gamma‐secretase inhibitor decreases amyloid‐beta production in the central nervous system”

Raybon, J. J., & Albright, C. F. (2010) · Annals of Neurology · doi:10.1002/ana.21929 · Cited by 2

Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-β After Inhibition of γ-Secretase

Siemers, E., Dean, R. A., Friedrich, S. W., Ferguson‐Sells, L. R., Gonzales, C., Farlow, M. R., & May, P. C. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31805b7660 · Cited by 154

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

Portelius, E., Dean, R. A., Gustavsson, M. K., Andréasson, U., Zetterberg, H., Siemers, E., & Blennow, K. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt30 · Cited by 92

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

Fleisher, A., Raman, R., Siemers, E., Becerra, L. M., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332